Vis AN - Search Results

1

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH. van der Cruijsen-Koeter IW, et al. Among authors: vis an. J Urol. 2005 Jul;174(1):121-5. doi: 10.1097/01.ju.0000162061.40533.0f. J Urol. 2005. PMID: 15947595 Clinical Trial.

2

Prostate cancer detection at low prostate specific antigen.

Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Schröder FH, et al. Among authors: vis an. J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.

3

Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections.

Vis AN, Kranse R, Nigg AL, van der Kwast TH. Vis AN, et al. Am J Clin Pathol. 2000 Mar;113(3):369-73. doi: 10.1309/CQWY-E3F6-9KDN-YV36. Am J Clin Pathol. 2000. PMID: 10705817

4

Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy.

Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH. Vis AN, et al. Urology. 2000 Oct 1;56(4):617-21. doi: 10.1016/s0090-4295(00)00681-6. Urology. 2000. PMID: 11018617

5

Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.

Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast TH. Vis AN, et al. J Urol. 2000 Dec;164(6):2156-61. J Urol. 2000. PMID: 11061947

6

Staging prostate cancer.

Hoedemaeker RF, Vis AN, Van Der Kwast TH. Hoedemaeker RF, et al. Among authors: vis an. Microsc Res Tech. 2000 Dec 1;51(5):423-9. doi: 10.1002/1097-0029(20001201)51:5<423::AID-JEMT4>3.0.CO;2-4. Microsc Res Tech. 2000. PMID: 11074612 Review.

7

Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schröder FH, Tanke HJ, van Dekken H. Alers JC, et al. Among authors: vis an. Am J Pathol. 2001 Feb;158(2):399-406. doi: 10.1016/s0002-9440(10)63983-1. Am J Pathol. 2001. PMID: 11159178 Free PMC article.

8

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Schröder FH, et al. Among authors: vis an. Urology. 2001 Jan;57(1):83-90. doi: 10.1016/s0090-4295(00)00863-3. Urology. 2001. PMID: 11164149 Clinical Trial.

9

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.

Vis AN, Hoedemaeker RF, van der Kwast TH, Schröder FH. Vis AN, et al. Prostate. 2001 Feb 1;46(2):154-62. doi: 10.1002/1097-0045(20010201)46:2<154::aid-pros1019>3.0.co;2-1. Prostate. 2001. PMID: 11170143 Clinical Trial.

10

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

161 results

Search Page